Tislelizumab/Chemotherapy Earns EU Approval in Nasopharyngeal Carcinoma
The European Union has endorsed the application of Tislelizumab, combined with Chemotherapy, for Nasopharyngeal Carcinoma treatment, taking a step forward in the field of oncology.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
Major Update: The Food and Drug Administration (FDA) issued a partial clinical hold on the Lorigerlimab trial in certain Gynecologic Cancers, triggered by certain safety events. Additional details were not provided at this time.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
In an endeavor to manage Immune-Checkpoint Inhibitor Toxicities in Melanoma efficiently, experts are developing refining management techniques. Detailed methodology is under review.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
Breaking News: Fast Track Designation has been granted by the FDA to SRN-101 for the treatment of recurrent high-grade glioma, marking another significant development in the field.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
A promising breakthrough in Multiple Myeloma treatments unveils a novel small molecule displaying early activity in pretreated cases. Research and trials are ongoing to measure its efficiency.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
A comparison study has been initiated to evaluate the impact of proton and photon therapies on the quality of life in OPSCC patients. Initial impressions are yet to be published.
